# In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

No. 1 6 -968 V (not to be published)

* * * * * * * * * * * * * * * * * * * * * * * * * HORACE MUNGIN, *

* Special Master Corcoran * Petitioner, * Filed: September 26, 2017 *

v. * * Decision by Stipulation; Damages; SECRETARY OF HEALTH * Prevnar 13 Pneumococcal Conjugate AND HUMAN SERVICES, * Vaccine ( “ Prevnar ” ); Shoulder Pain; * Arm Cellulitis; Index Finger Stenosing Respondent. * Tenosynovitis. * * * * * * * * * * * * * * * * * * * * * * * * * *

Jeffrey S. Pop , Jeffrey S. Pop & Associates, Beverly Hills, CA

, for Petitioner.

Douglas Ross

, U.S. Dep’t of Justice, Washington, DC, for Respondent.

DECISION AWARDING DAMAGES 1

On August 9, 2016, Horace Mungin filed a petition seeking compensation under the National Vaccine Injury Compensation Program (“Vaccine Program”). 2 Petitioner alleges that he suffered from left shoulder pain, left arm cellulitis, and index finger stenosing tenosynovitis as a
result of h is July 2 1 , 2015, Prevnar 13 pneumococcal conjugate ( “ Prevnar ” ) vaccine. Petitioner
further alleges that he has experienced the residual effects of this condition for more than six
months

.

1 Although this Decision has been formally designated “not to be published,” it w ill nevertheless be posted on the Cou rt of Federal Claims’s website in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012). This means the ruling will be available to anyone with access to the internet . As provided by 42 U.S.C. § 300aa12(d)(4)(B), however, the parties may object to the decision’s inclusion of certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party has fourteen days within which to re quest redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the whole decision in its present form will be available. Id

.

2 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3758, codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (20 12) (“Vaccine Act” or “the Act”)

.2

Respondent denies that the Prevnar vaccine caused Petitioner’s left shoulder pain, left arm cellulitis, index finger stenosing tenosynovitis, or any other injury

. Nonetheless both parties, while maintaining their above

- stated positions, agreed in a stipulation (filed on S eptember 25 , 2017 ) that the issues before them could be settled, and that a decision should be entered awarding Petitione r compensation.

I have reviewed the file, and based upon that review, I conclude that the parties’ stipulation (as attached hereto) is reasonable. I therefore adopt it as my decision in awarding damages on the
terms set forth therein.

The stipulation awards:

 A lump sum of $ 10 ,000.00 in the form o f a check payable to Petitioner.

Stipulation ¶ 8. This amount represents compensation for all damages that would be available under Section 15(a) of the Act.

I approve a Vaccine Program award in the requested amount set forth above to be made to Petitioner. In the absence of a motion for review filed pursuant to RCFC Appendix B, the clerk of the Court is directed to enter judgment herewith. 3

IT IS SO ORDERED.

/s/ Brian H. Corcoran Brian H. Corcoran Special Master

3 Pursuant to Vaccine Rule 11(a), the parties may expedite entry of judgment by each filing (either jointly or separately) a notice renouncing their right to seek review.